Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BI, Vanderbilt announce third collaboration
April 2018
SHARING OPTIONS:

INGELHEIM, Germany & NASHVILLE, Tenn.—Boehringer Ingelheim (BI) and Vanderbilt University are expanding their current collaboration to develop novel anticancer compounds, with the expanded deal to focus on discovering and developing new chemical therapeutics that target the pro-survival protein MCL1 as a therapy against MCL1-dependent cancers. Though no specific financial details were disclosed, the agreement includes upfront and milestone payments.
 
“Boehringer Ingelheim and Vanderbilt University have the expertise and are jointly focused on discovering breakthrough medicines against the cancer causing proteins KRAS, SOS and now, MCL1,” Dr. Darryl McConnell, vice president and research site head at Boehringer Ingelheim, Austria, remarked in a press release. “Together, we are committed to driving scientific research and development forward to help patients win the fight against cancer.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.